Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing Mouthwash
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone Receptor Positive Breast Cancer
Conditions
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
Trial Timeline
Jan 31, 2018 → Jan 1, 2027
NCT ID
NCT03401385About Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing Mouthwash
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing Mouthwash is a phase 1 stage product being developed by Daiichi Sankyo for Hormone Receptor Positive Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03401385. Target conditions include Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer.
What happened to similar drugs?
9 of 20 similar drugs in Hormone Receptor Positive Breast Cancer were approved
Approved (9) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03401385 | Phase 1 | Active |
Competing Products
20 competing products in Hormone Receptor Positive Breast Cancer